Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial.

The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates.

Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up.

This is in direct comparison to survival expectations of around 7 months for patients after first line therapy.

Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients.

Chimeric is now opened enrolment for the phase 1B stage of the trials.

Articles:
https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/
https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/
https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/
https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/

For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/asx-chm/